KEGG   DISEASE: Hypertriglyceridemia
Entry
H01637                      Disease                                

Name
Hypertriglyceridemia
Description
Hypertriglyceridemia (HTG) is a condition with fasting triglyceride (TG) levels in blood continuing to rise. HTG generally refers to an increase of plasma triglyceride (TG) concentrations above the 95th percentile for age and gender of a reference population. HTG has generally been classified as primary when a definite familial or inherited basis is suspected, whereas secondary HTG refers to cases where there coexist one or more identifiable secondary conditions such as metabolic syndrome, type 2 diabetes (T2D), alcohol consumption, various medications, renal insufficiency, pregnancy, etc. Genetic conditions with HTG include familial HTG (FHTG), familial combined hyperlipidemia (FCHL) [DS:H00153], and familial dysbetalipoproteinemia (Type III hyperlipidemia) [DS:H00156]. Three drug classes are clinically available for treatment of HTG, fibrates, niacin and n-3 fatty acids. Each of these classes has limitations. There is inconsistency in the evidence base for cardiovascular risk reduction using fibrates, the use of niacin is associated with significant side effects, and there are limited data on the use of n-3 fatty acids to reduce cardiovascular risk.
Category
Metabolic disease
Brite
Human diseases [BR:br08402]
 Congenital disorders of metabolism
  Congenital disorders of lipid/glycolipid metabolism
   H01637  Hypertriglyceridemia
Human diseases in ICD-11 classification [BR:br08403]
 05 Endocrine, nutritional or metabolic diseases
  Metabolic disorders
   Disorders of lipoprotein metabolism or certain specified lipidaemias
    5C80  Hyperlipoproteinaemia
     H01637  Hypertriglyceridemia
Related
pathway
hsa04979  Cholesterol metabolism
hsa00561  Glycerolipid metabolism
Gene
USF1 [HSA:7391] [KO:K09106]
APOE [HSA:348] [KO:K04524]
LPL [HSA:4023] [KO:K01059]
Drug
Niacin [DR:D00049]
Rosuvastatin calcium [DR:D01915]
Fenofibrate [DR:D00565]
Choline fenofibrate [DR:D08890]
Icosapent ethyl [DR:D01892]
Omega-3-acid ethyl esters [DR:D05255]
Fenofibric acid [DR:D11579]
Other DBs
ICD-11: 5C80.1
ICD-10: E78.1 E78.2 E78.4
MeSH: D015228
OMIM: 144250 617347
Reference
  Authors
Lewis GF, Xiao C, Hegele RA
  Title
Hypertriglyceridemia in the genomic era: a new paradigm.
  Journal
Endocr Rev 36:131-47 (2015)
DOI:10.1210/er.2014-1062
Reference
  Authors
Sahebkar A, Watts GF
  Title
Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?
  Journal
Expert Rev Clin Pharmacol 8:363-6 (2015)
DOI:10.1586/17512433.2015.1045880
Reference
  Authors
Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A
  Title
Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.
  Journal
Best Pract Res Clin Endocrinol Metab 28:423-37 (2014)
DOI:10.1016/j.beem.2013.10.002
Reference
PMID:23009777 (drug)
  Authors
Maki KC, Bays HE, Dicklin MR
  Title
Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence.
  Journal
J Clin Lipidol 6:413-26 (2012)
DOI:10.1016/j.jacl.2012.04.003
LinkDB

» Japanese version

DBGET integrated database retrieval system